Tesaro (TSRO) Risk-Reward May Not be Favorable But Stock Has Upside Drivers, Says RBC; Analyst Maintains 'Outperform'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/26/2024
- Stocks face worst month since September, yen swings after BoJ
- Microsoft fiscal Q3 results top estimates as AI revolution spurs cloud growth
- Alphabet stock surges 11% to record high on Q1 earnings beat, first-ever dividend
- Intel slides in afterhours trading as Q1 revenue misses, Q2 outlook falls short
- Oil prices on track to snap two-week losing streak
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- Union Pacific beats profit estimates on stronger pricing, resumes share buyback
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hertz Global (HTZ) misses earnings expectations as fleet costs weigh
- Teladoc (TDOC) Misses Q1 EPS by 3c, offers outlook
- After-hours movers: Alphabet, Microsoft, Snap, Intel, and more
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
Tesaro (TSRO) Weakness a 'Clear Buying Opportunity' - Leerink Partners
August 24, 2016 7:24 AM EDTLeerink Partners analyst Seamus Fernandez reiterated an Outperform rating and $108 price target on Tesaro (NASDAQ: TSRO), saying weakness in the stock on on the recent NDA submission of CLVS (NR) rucaparib for 3L+ BRCA-mutated ovarian cancer, as well as the circulation of perceived controversies pertaining to niraparib, creates a "clear buying opportunity."
Fernandez said their review of FDA... More
TESARO (TSRO) Lower Following Negative Report
August 23, 2016 12:41 PM EDTTESARO (NASDAQ: TSRO) is weak Tuesday following a negative research reports from Favus. The firm sees downside risk and notes Clovis Oncology, Inc. (NASDAQ: CLVS) data may pressure the stock. Shares of TSRO are down 5%.
... More
